Shanwai Shan (688410.SH) spent a total of 30,098,550 yuan to repurchase 0.53% of its shares.

On June 3rd, Gelunhui reported that up until May 31, 2024, the company had repurchased 1,151,023 of its own shares, accounting for 0.53% of the total share capital of 215,648,085 shares. The highest purchase price was 27.30 yuan/share, the lowest was 25.17 yuan/share, and the total amount paid was RMB 30,098,550.45 (excluding stamp duty, transaction fees, and other transaction costs).

Gelonghui FinanceJun 3 05:26 ET

Calculating The Fair Value Of SWS Hemodialysis Care Co., Ltd. (SHSE:688410)

Key Insights Using the 2 Stage Free Cash Flow to Equity, SWS Hemodialysis Care fair value estimate is CN¥23.84 SWS Hemodialysis Care's CN¥22.12 share price indicates it is trading at similar levels

Simply Wall StMay 29 19:25 ET

Mountain Wai Shan (688410.SH): The consumables sector maintained a continuous high growth rate in the first quarter, with a year-on-year increase of 30%

Gelonghui, May 16, 丨 Shanwaishan (688410.SH) disclosed an investor relations activity record sheet showing that, relying on the industrial foundation, scientific research platform and resource advantages of Shanwaishan Company, the subsidiaries of Shanwaishan Company, Tianwaitian and Delaifu have continuously strengthened the development foundation and soft and hard strength of scientific research and development, product quality, manufacturing, etc., and have successively obtained hemodialysis/powders, hemodialyzers, dialysate filters, continuous blood purification pipelines, hemoperfusion devices and other series of registration certificates for blood purification consumables. Self-produced blood purification supplies are fully launched for Shanwaishan Company

Gelonghui FinanceMay 16 03:57 ET

Mountain Wai Shan (688410.SH): Blood purification equipment achieved revenue of 118 million yuan in the first quarter, and the dialysis machine market continued to gain strength

Gelonghui, May 16丨Shanwaishan (688410.SH) disclosed an investor relations activity record table showing that in 2023, the company's hemodialysis machines and continuous blood purification equipment (CRRT) grew strongly, achieving revenue of 528 million yuan, ranking first in the industry in terms of market share growth. Among them, CRRT products were driven by the critical care capacity building policy, which increased sharply by nearly 3 times over the previous year, and quickly became the largest market share of continuous blood purification equipment. The growth of dialysis machines showed a trend where domestic and foreign markets went hand in hand. Domestic sales achieved a 124% year-on-year increase in revenue, leading the way for domestic independent brands

Gelonghui FinanceMay 16 03:56 ET

Mountain Wai Shan (688410.SH): A total of 0.53% of the company's shares have been repurchased

Gelonghui, May 6, 丨 Shanwaishan (688410.SH) announced that as of April 30, 2024, the company had repurchased a total of 1,151,023 shares, accounting for 0.53% of the company's total share capital of 215,648,085 shares. The highest repurchase transaction price was 27.30 yuan/share, the lowest price was 25.17 yuan/share, and the total capital paid was RMB 30,098,550.45 (excluding transaction fees such as stamp duty and transaction commissions).

Gelonghui FinanceMay 6 06:40 ET

Shanwaishan (688410.SH) announced first-quarter results, net profit of 34.23 million yuan, a year-on-year decrease of 54.1%

Mountain Wai Shan (688410.SH) disclosed its report for the first quarter of 2024. The company achieved revenue of 1.62 during the reporting period...

Zhitong FinanceApr 25 06:36 ET